Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition
礼来以24亿美元收购奥尔纳治疗技术公司，加入体内CAR-T竞速

Eli Lilly will buy Orna Therapeutics to get a hold of its immune system-resetting pipeline and enter the in vivo CAR-T cell therapy race.
礼来将收购奥尔纳治疗技术公司，以获取其“重置免疫系统”的在研管线，并进军体内CAR-T细胞疗法赛道。